Biogen Expands Portfolio with Neomorph Molecular Glues Deal Worth Up to $1.45 Billion

Deal Value:
Biogen has entered into a deal with Neomorph worth up to $1.45 billion for molecular glues technology.

Molecular Glues:
Molecular glues are a promising therapeutic approach that can stabilize proteins and modulate their interactions, offering potential treatments for various diseases.

Neomorph Benefits:
Neomorph will receive an upfront payment and is eligible for additional payments based on preclinical, clinical, regulatory, commercial, and sales milestones.

Biogen's Expansion:
This deal marks Biogen's entry into the molecular glues space, expanding its portfolio and capabilities in biotechnology.

Recent Developments:
Biogen has also recently reported strong Q3 results, raising its 2024 EPS guidance, and has seen positive outcomes in its Phase II/III study for a higher dose of Spinraza in treating spinal muscular atrophy.